
TherapeuticsMD has succeeded in changing the FDA’s mind on its Imvexxy product, after an initial rejection in May of last …

It looked unlikely that Fasenra would achieve success in the chronic obstructive pulmonary disease (COPD) area, after it suffered in …

On the day that news broke, through Pulse, that over a million patients have had to move GP surgery in …

Tim de Gavre has been announced as the new chair for the British Generic Manufacturers Association (BGMA), a position he …

BioMarin is confident that its newly approved treatment for phenylketonuria (PKU) is set to become a blockbuster and it’s priced the …

The news broke at the start of the month that a number of women who should have been invited to …

Prothena Therapeutics has acted drastically by slashing staff numbers by more than half, after the failure of two pivotal trials …

Pharmafocus spoke to John Crowley, CEO of Amicus Therapeutics, about his highly unusual career in the pharmaceutical and biotech industries.

Astellas, under the direction of new CEO, Kenji Yasukawa, has unveiled a major new restructure, ahead of a difficult looking …

A report published by the Institute for Fiscal Studies (IFS) has stressed that UK funding into the NHS needs to …

MSD Keytruda has enjoyed the most success of the PD-1/L1 therapies in clinical trials recently and it’s rapidly cementing its …

The joint partnership between Vifor Pharma and Fresenius Medical Care, Vifor Fresenius, has put down $50 in upfront cash and …

The latest global research paints a bleak picture of future global public health, predicting that almost a quarter of the …

Much has already been written about Takeda and its massive financial stretch to pull in the Shire acquisition, in the …

The Royal Liverpool and Broadgreen University Hospitals NHS Trust has teamed up with a provider of AI systems to introduce …